Dudediligence.

SCYNEXIS, Inc

SCYXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$660,000Sep ’24$977,000Dec ’24$257,000Mar ’25$1.4MJun ’25$334,000Sep ’25$18.6MDec ’25$0.00Mar ’26$235,000Jun ’26
Net income, by quarter
−$2.8MSep ’24−$4.4MDec ’24−$5.4MMar ’25−$6.9MJun ’25−$8.6MSep ’25$12.3MDec ’25−$21.3MMar ’26$7.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$13.2M$5.1M$140.1M$3.7M$20.6M
Operating income−$60.8M−$85.8M$72.7M−$37.1M−$16.1M
Net income−$32.9M−$62.8M$67.0M−$21.3M−$8.6M
Operating cash flow−$54.6M−$79.9M$60.2M−$24.0M−$5.3M
Free cash flow−$54.6Mnone on filenone on filenone on filenone on file
Cash$104.5M$45.8M$34.0M$16.1M$21.3M
Debt$34.4Mnone on filenone on filenone on filenone on file
Shares outstanding28.7M32.7M37.2M38.0M43.5M